[Renal protection in the patients with idiopathic hypertensia: the possibilities of the combined blockade of the reninangiotensinaldosterone system].

Reninangiotensinaldosterone system is a key link in regulation of blood pressure and causes the target organ damage in hypertensive patients. For many years is not lost interest in the pharmacological blockade of RAAS in order to achieve target levels of BP and prevent damage target organs, particularly kidneys. Most recently recommended for clinical application of direct rennin inhibitor--aliskiren, a number of researcher have proven expressed nephroprotective effect. However, at present there is no unequivocal answer to the question whether there are advantages in combined RAAS blockade in hypertensive patients with use of aliskiren and angiotensinconverting enzyme inhibitor or angiotensin receptor blocker.

[Impairment of antiviral cellular resistance and possibilities of its correction during acute altitude hypoxia]. / Narushenie protivovirusnoi kletochnoi rezistentnosti i vozmozhnosti ee korrektsii pri ostroi vysotnoi gipoksii.

Antiviral cell resistance of blood monocytes and lymphocytes was studied in 29 healthy human subjects subjected to acute altitude hypoxia (AAH) in climatic chamber TABAI, and 39 healthy males during rapid ascent from the sea level up to 3250 m. The antiviral resistance of immune cells was found to be suppressed by AAH. Double blind method was used to compare effects of placebo, dexamethasone and olifen (approved by the Pharmacology Committee of the Russian Ministry of Health as an antihypoxic preparation) on the antiviral resistance of cells during AAH. Unlike dexamethasone, from the onset of AAH olifen prevented decline of the antiviral resistance of cells; olifen successfully remedied disorders resulted from stay in AAH.

[Olifen action on mutagenesis in human lymphocytes]. / Vliianie olifena na mutagenez v limfotsitakh cheloveka.

Antihypoxic drug olifen has been studied for effect in 72-hour PHA-stimulated cultures of blood lymphocytes in 15 healthy donors and 35 patients with diseases accompanied by enhanced mutagenesis in lymphocytes (rheumatoid arthritis, systemic lupus erythematosus, hypophyseal adenoma, neoplasms, chronic intoxications). Olifen has no mutagenic effect on mutagenesis in lymphocytes in a wide dose range. In diseases with intensive mutagenesis in lymphocytes olifen exhibits antimutagenic effect without lymphopoiesis.